Work

Cost-utility analysis of HPV-cytology co-testing in the Korean national cervical cancer screening program

Year: 2027
Type: article
Abstract: OBJECTIVE: To evaluate the cost-utility of incorporating human papillomavirus (HPV) testing into the Korean National Cervical Cancer Screening Program, across 30 strategies. METHODS: A Markov model of cervical cancer compared no screening, cytology screening, and HPV-cytology co-testing among women aged ≥20 years from the healthcare system perspective over a lifetime horizon. Natural-history parameters were calibrated to age-specific incidence in the Korea Central Cancer Registry. Costs and quality-adjusted life years (QALYs) were discounted at 4.5%, and a willingness-to-pay (WTP) threshold of 30 million Korean won (KRW) per QALY applied. RESULTS: Compared with no screening, biennial cytology had an incremental cost-effectiveness ratio (ICER) of 1.8 million KRW/QALY, 6% of the WTP threshold. Only 4 of the 26 co-testing strategies remained on the efficiency frontier, and none was cost-effective: ICERs versus biennial cytology ranged from 100.5 million KRW/QALY for the most efficient strategy (biennial co-testing at ages 35-70 years with biennial cytology at other ages) to 118.4 million KRW/QALY for biennial co-testing at all ages, 3.4-3.9 times the threshold. Findings were unchanged at 0% and 3% discount rates and in one-way sensitivity analyses; biennial cytology was optimal in 99.6% of probabilistic simulations. Even the most efficient co-testing strategy would become cost-effective only if the HPV test price fell below 19,007 KRW. CONCLUSION: These findings suggest that biennial cytology remains economically efficient under current Korean conditions and that the addition of HPV testing would not be cost-effective at the present WTP threshold. Reconsideration may be warranted if HPV testing costs decrease substantially.
Language: English
Subfield: Epidemiology
Field: Medicine
Open Access status: diamond
OpenAlex ID: W7234272988
Cites: 30
Cited by:
Related to: 10